Kurkunpään kroonisen tulehduksen ja syövän esiasteiden mikrobilääkehoito -tutkimusprojekti

Laryngeaalisen leukoplakian mikrobilääkehoito -tutkimusprojekti - LARLEUKO

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-006011-23-FI

Enrollment

Registered

2021-01-25

Start date

2021-03-02

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Krooninen laryngiitti

Interventions

Trade Name: Diflucan Pharmaceutical Form: Capsule Other descriptive name: FLUCONAZOLE Trade Name: Kefexin Product Name: Kefexin Pharmaceutical Form: Tablet CAS Number: 23325-78-2 Other descriptive na

Eligibility

Inclusion criteria

Inclusion criteria: Krooninen laryngiitti ja leukoplakia Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria: Antibioottiallergia ja lääkeaineinteraktion riski

Design outcomes

Primary

Measure	Time frame
Main Objective: Kurkunpäätulehduksen ja leukoplakian paraneminen;Secondary Objective: Äänen paraneminen;Primary end point(s): Laryngiitin ja leukoplakian paraneminen;Timepoint(s) of evaluation of this end point: 2, 4 ja 6 viikkoa	—

Secondary

Measure	Time frame
Secondary end point(s): Äänen paraneminen;Timepoint(s) of evaluation of this end point: 2, 4 ja 6 viikkoa	—

Countries

Finland

Contacts

Public Contactno

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026